Recent developments in the use of oral anticoagulants

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1769-1781

  Lassen, Michael R ^a  

^a Hoersholm Hospital   (Denmark)

Author keywords

Anticoagulants; Arthroplasty; Factor Xa; Hip; Knee; Orthopaedics

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DU 176B; ECARIN; ENOXAPARIN; GLYCOPROTEIN P; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTON PUMP INHIBITOR; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AREA UNDER THE CURVE; BLEEDING; CLINICAL TRIAL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; LIVER INJURY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REPRODUCTIVE TOXICITY; REVIEW; SEX DIFFERENCE; STROKE; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG MONITORING; HUMANS; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOEMBOLISM;

EID: 68149123346     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903042325     Document Type: Review

References (62)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-764
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:381S-453S •• These are the comprehensive American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, which update the guidelines written in 2004. (Pubitemid 351894916)
3. Borris LC, Breindahl M, Lassen MR, et al. Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events. J Thromb Haemost 2008;6:1671-1679
4. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009;123:488-497
5. Sanofi-aventis. Clexane summary of product characteristics 2008. Available from: http:// emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid = 12847 [Last accessed 22 January 2009]
6. Wienen W, Stassen JM, Priepke H. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-162 (Pubitemid 47078782)
7. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabol Dispos 2008;36:386-399 (Pubitemid 351185753)
8. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59 (Pubitemid 350260888)
9. Boehringer Ingelheim. Pradaxa summary of product characteristics 2009. Available from: http://emc.medicines.org. uk/document.aspx?documentId = 20760 [Last accessed 14 April 2009]
10. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-563 (Pubitemid 40562946)
11. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004;2:1573-1580 • This dose-ranging safety study showed that dabigatran, at the studied doses, has an acceptable safety profile. (Pubitemid 40186173)
12. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111
13. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303 (Pubitemid 47283865)
14. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Throm Haemost 2007;5(Suppl 1):60-64
15. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-1514 • Findings from BISTRO I were confirmed in this larger study. It also demonstrated that oral dabigatran, started early in the postoperative period, was effective and well tolerated across a range of doses.
16. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-829
17. Pinto D, Orwat M, Koch S, et al. Discovery pf 1-(4-methoxyphenyl)-7-oxo- 6-(4-(2-oxyopiperidin-1-yl) phenyl)-4,5,6,7-tetrahydro1-H-pyrazaolo {3,4-c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-5356
18. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics following oral administration to humans. Drug Metab Dispos 2009;37:74-81
19. Wang L, Raghavan N, He K, et al. Sulfation of O-demethyl apixaban: Enzyme identification and species comparison. Drug Metab Dispos 2009;37:802-808
20. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Thromb Haemost 2007;5:2368-2375 • This study showed that apixaban 5-20 mg/day had a promising benefit-risk profile for VTE prevention in TKR patients. (Pubitemid 350154345)
21. Feng Y, Li LY, Shenker A, et al. Exposure-clinical outcome modeling and simulation to facilitate dose selection of apixaban in subjects undergoing elective total knee replacement surgery [abstract P-M-663]. J Thromb Haemost 2007;5(Suppl 2)
22. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects [abstract P-M-664]. J Thromb Haemost 2007;5(Suppl 1)
23. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521
24. Kubitza D, Becka M, Wensig G, et al. Safety, pharmacodynamics and pharmacokinetics of BAY 597939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880 (Pubitemid 41803696)
25. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939---an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521
26. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor [abstract 905]. Blood 2006;108
27. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47:218-226 (Pubitemid 46146488)
28. Bayer HealthCare. Xarelto/rivaroxaban summary of product characteristics 2008. Available from: http://emc.medicines.org. uk/emc/industry/default.asp?page = displaydoc.asp&documentid = 21265 [Last accessed 28 January 2009]
29. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-558
30. Kubitza D, Becka M, Zuehlsdorf M. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin [abstract 702]. J Clin Pharmacol 2006;46
31. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007;63:469-476 (Pubitemid 46426627)
32. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007;120:685-693 (Pubitemid 47268049)
33. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3:2479-2486
34. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128
35. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-2381
36. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor xa inhibitor: in vitro and vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-1549
37. Daiichi Sankyo Europe. Daiichi Sankyo announces clinical study data for oral factor Xa inhibitor DU-176b. Press release 2 September 2008. Available from: http://www.daiichi-sankyo.eu/site- eu/?node-id = 2674 [Last accessed 17 April 2009]
38. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185 (Pubitemid 47617868)
39. RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
40. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956 (Pubitemid 47393577)
41. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
42. BMS news release. Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program, 27 August 2008. Available from: http://newsroom.bms.com/article-display. cfm?article-id = 5371 [Last accessed 16 January 2009]
43. Lassen M, Gallus A, Pineo G, Raskob G, ADVANCE-1 Investigators. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial. Blood (ASH Annual Meeting Abstracts) 2008;112:31
44. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775 • This study demonstrated that a once-daily oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily 40 mg subcutaneous dose of enoxaparin after elective THR, while bleeding rates were similar to those of enoxaparin.
45. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39 •• This study was a regimen-regimen comparison (extended rivaroxaban versus the European regimen of enoxaparin). It showed that rivaroxaban was significantly more effective than enoxaparin plus placebo in preventing the primary outcome after THR, while bleeding rates were similar to those of enoxaparin.
46. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786 • This study demonstrated that rivaroxaban was significantly more effective for thromboprophylaxis than enoxaparin after elective TKR, while bleeding rates were similar to those of enoxaparin. (Pubitemid 351930852)
47. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680
48. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009;91:636-644
49. Boehringer Ingelheim. RE-VOLUTION study brochure 2008. Available from: http://www.boehringer-ingelheim.com/ corporate/news/information-packs/acd.asp.
50. Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-1318
51. Agnelli G, Gallus A, Goldhaber S, et al. Treatment of proximal deep vein thrombosis with oral, direct Factor Xa inhibitor rivaroxaban (BAY-59 7939): the ODIXa-DVT (Oral Direct Factor Xa Treatment of Proximal Deep-Vein Thrombosis) study. Circulation 2007;116:180-187
52. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008;112:2242-2247
53. Alexander JH, Wallentin L. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndrome: results of the APPRAISE-I dose guiding trial. Presented at the European Society of Cardiology congress, 2008, Munich, Germany. Available from: http://spo.escardio. org/ eslides/search.aspx?eevtid = 24 [Last accessed 12 January 2009]
54. Gibson CM, Mega JL, Hammett CJ, et al. Randomized comparison of rivaroxaban, an oral direct Factor Xa inhibitor, with placebo in patients with acute coronary syndromes: the ATLAS ACS-TIMI 46 trial [abstract]. Circulation 2008;118;2311
55. Johnson and Johnson. Rivaroxaban phase II dose-ranging study demonstrates encouraging response rates in treatment of acute coronary syndrome patients. Press release. 10 November 2008. Available from: http://www.jnj.com/connect/ news/ all/2008/1110-080000 [Last accessed 21 January 2009]
56. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-1426 (Pubitemid 47576022)
57. Nagarakanti R, Ezekowitz MD, Parcham-Azad K, et al. Long-term open label extension of the prevention of embolic and thrombotic events study in patients with atrial fibrillation randomized to dabigatran (PETRO-Ex study). Poster presentation at the 80th Congress of the American Heart Association, 8-11 Nov 2008, New Orleans, USA
58. Bayer Healthcare. Stroke prevention in atrial fibrillation: ROCKET-AF. Available from: http://xarelto.com/scripts/ pages/en/clinical-studies/ strokeprevention- in-atrial-fibrillation/index.php [Last accessed 21 January 2009]
59. Weitz JI, Connolly SJ, Kunitada S, et al. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract 33]. Blood (ASH Annual Meeting Abstracts) 2008;112
60. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009;31:194-212
61. Diamantopoulos A, Forster F, Brosa M, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress, 8-11 Nov 2008, Athens, Greece
62. Dahl OE, Borris LC, Bergqvist D, et al. Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. Int Angiol 2008;27:60-67